FDA's CBD Enforcement Policy Report To Congress May Have Offered More Questions Than Answers
Executive Summary
Attorney Libby Baney manages and represents the Collaborative for CBD Science and Safety and has suggestions for additional questions the FDA should answer about CBD safety before it opens a regulatory path for its lawful use in non-drug products. FDA's recent report to Congress "left many searching for more guidance from the agency on what comes next as it does not offer any recommendations around the future of the agency’s oversight of the CBD industry," Baney says.